Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/25/2024 | $12.00 → $4.00 | Outperform → Market Perform | Leerink Partners |
| 6/8/2023 | $13.00 | Outperform | SVB Securities |
| 1/19/2023 | $8.00 → $18.00 | Neutral → Buy | UBS |
| 1/9/2023 | $9.00 → $21.00 | Hold → Buy | Jefferies |
| 1/21/2022 | $55.00 → $20.00 | Neutral → Underperform | B of A Securities |
| 1/18/2022 | $52.00 | Market Outperform | JMP Securities |
| 10/22/2021 | $35.00 | Hold | Deutsche Bank |
Leerink Partners downgraded CureVac from Outperform to Market Perform and set a new price target of $4.00 from $12.00 previously
SVB Securities initiated coverage of CureVac with a rating of Outperform and set a new price target of $13.00
UBS upgraded CureVac from Neutral to Buy and set a new price target of $18.00 from $8.00 previously
Experienced CFO and investment banker with 30-year track record will help drive CureVac's transformationTÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / November 4, 2024 / CureVac N.V. (NASDAQ:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced the appointment of Axel Sven Malkomes as Chief Financial Officer, effective November 11, 2024.Mr. Malkomes joins CureVac at a pivotal moment as the company enters a new chapter of growth and innovation, bringing over three decades of senior corporate and investment banking experience within the biotech and pharmaceutical industries."Axel's
Agomab Therapeutics NV (‘Agomab') today announced that Pierre Kemula will join the company as Chief Financial Officer (CFO) effective November 1, 2024, bringing more than 15 years of experience in global biotech financial leadership. Mr. Kemula joins Agomab from CureVac N.V. (NASDAQ:CVAC), where he currently serves as CFO. In this role, Mr. Kemula has led CureVac's financial and capital markets activities since 2016, characterized by a successful listing on Nasdaq and two subsequent follow-on offerings. Under his leadership, CureVac raised over $1.6 billion in equity. Mr. Kemula will succeed Tolga Hassan, who has recently left the company to explore new opportunities closer to home. Follo
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / June 24, 2024 / CureVac N.V. (NASDAQ:CVAC), a global clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced the voting results of the Company's annual general meeting.The shareholders of the Company voted in favor of all proposals. These proposals included the appointment of Thaminda Ramanayake and the reappointment of Malte Greune as members of the Management Board, both effective June 24th, 2024. Additionally, Jean Stéphenne and Mathias Hothum were reappointed as members of the supervisory board, Birgit Hofmann was appointed as a new member of t
New trial date for U.S. patent litigation set for March 3, 2025, following settlement with Acuitas Therapeutics. First instance decision on validity of EP 3 708 668 B1 (split poly-A tail technology) scheduled for March 25, 2025, by European Patent Office in the context of the German patent litigation UK trial on validity of intellectual property rights EP 3 708 668 B1 and EP 4 023 755 B1 (split poly-A tail technology) began July 10; judgement expected later in 2024
JMP Securities analyst Roy Buchanan reiterates CureVac (NASDAQ:CVAC) with a Market Outperform and maintains $18 price target.
Wednesday, GSK plc (NYSE:GSK) and CureVac N.V. (NASDAQ:CVAC) announced they have restructured their existing collaboration into a new licensing agreement, allowing the companies to prioritize investment and focus on its respective mRNA development activities. Since 2020, GSK and CureVac have worked together to develop mRNA vaccines for infectious diseases. Through this collaboration, GSK and CureVac have vaccine candidates for seasonal influenza and COVID-19 in Phase 2 and avian influenza in Phase 1 clinical development. All candidates are based on CureVac's proprietary second-generation mRNA backbone. Also Read: CureVac, GSK Partner Release Data On Influenza Vaccine Study. GS
6-K - CureVac N.V. (0001809122) (Filer)
6-K - CureVac N.V. (0001809122) (Filer)
6-K - CureVac N.V. (0001809122) (Filer)
Strengthened Cash, Strategic Refocus and Pipeline Progress Define Transformative Quarter€400 million upfront payment from restructured GSK collaboration reflected in financials, cash position increased to €551 million; expected cash runway re-affirmed into 2028CVGBM Phase 1 glioblastoma study showed 77% of patients with antigen-specific T-cell responses; data presented at ESMO, SITC and SNONew off-the-shelf program for squamous non-small cell lung cancer started, expected to enter Phase 1 in H2 2025New preclinical prophylactic vaccine program for urinary tract infections initiated, supported by positive preclinical data versus protein-based vaccinesPositive Phase 2 data from seasonal influen
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / November 7, 2024 / CureVac N.V. (NASDAQ:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), will report financial results, and provide business updates for the third quarter and first nine months 2024 on Tuesday, November 12, 2024. The company will host a conference call and webcast on the same day at3 p.m. CET / 9 a.m. EST.Dial-in numbers to participate in the conference call:U.S. Toll-Free: +1-877-407-0989International: +1-201-389-0921Germany: 0800-182-0040 (landline access) / 0800-184-4713 (cell phone access)The live webcast link can be accesse
Closed new licensing agreement with GSK worth up to €1.45 billion, including €400 million upfront; provides strong validation of CureVac's mRNA platformInitiated strategic workforce reduction of ~30% by end of 2024, optimizing business to focus on high-value opportunities in oncology, infectious diseases and other areasInvoiced €10 million milestone payment after Phase 2 transition of pre-pandemic avian influenza (H5N1) program; candidate fully licensed to GSK under new agreementDosing of first patient in Phase 1 study Part B in glioblastoma with CVGBM to establish dose-confirmation; initial dose-escalation Part A data accepted for oral presentation at ESMOStrengthening of Supervisory Board
SC 13G/A - CureVac N.V. (0001809122) (Subject)
SC 13G/A - CureVac N.V. (0001809122) (Subject)
SC 13G - CureVac N.V. (0001809122) (Subject)
Strengthened Cash, Strategic Refocus and Pipeline Progress Define Transformative Quarter€400 million upfront payment from restructured GSK collaboration reflected in financials, cash position increased to €551 million; expected cash runway re-affirmed into 2028CVGBM Phase 1 glioblastoma study showed 77% of patients with antigen-specific T-cell responses; data presented at ESMO, SITC and SNONew off-the-shelf program for squamous non-small cell lung cancer started, expected to enter Phase 1 in H2 2025New preclinical prophylactic vaccine program for urinary tract infections initiated, supported by positive preclinical data versus protein-based vaccinesPositive Phase 2 data from seasonal influen
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / November 7, 2024 / CureVac N.V. (NASDAQ:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), will report financial results, and provide business updates for the third quarter and first nine months 2024 on Tuesday, November 12, 2024. The company will host a conference call and webcast on the same day at3 p.m. CET / 9 a.m. EST.Dial-in numbers to participate in the conference call:U.S. Toll-Free: +1-877-407-0989International: +1-201-389-0921Germany: 0800-182-0040 (landline access) / 0800-184-4713 (cell phone access)The live webcast link can be accesse
Experienced CFO and investment banker with 30-year track record will help drive CureVac's transformationTÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / November 4, 2024 / CureVac N.V. (NASDAQ:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced the appointment of Axel Sven Malkomes as Chief Financial Officer, effective November 11, 2024.Mr. Malkomes joins CureVac at a pivotal moment as the company enters a new chapter of growth and innovation, bringing over three decades of senior corporate and investment banking experience within the biotech and pharmaceutical industries."Axel's